NeoDynamics Announces Delivery of CorePulse Needles to 23 Hospitals
STOCKHOLM – April 3, 2023, NeoDynamics AB (publ) (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, today announced that the first production run of its CorePulse needles has been shipped and is anticipated to arrive with UK and German customers this month.
NeoDynamics is pleased it will now deliver CorePulse needles in April and VacuPulse needles by mid-year to the centres in Europe listed below.
The following hospitals will receive deliveries in April 2023:
| UK | Germany and Switzerland |
| Nightingale Centre (Manchester) | Hermann-Joseph Krankenhaus (Erkelenz) |
| Leeds Teaching Hospital | Klinikzentrum Mitte (Dortmund) |
| Western General Hospital (Edinburgh) | Johanniter Bonn |
| Darlington Memorial Hospital | Marienhospital Bottrop |
| North Manchester General Hospital | Krankenhaus Düren |
| The Royal Oldham Hospital | Klinikum Stadt Soest |
| Cheltenham General Hospital | Klinikum Lüneburg |
| Wycombe Hospital | Klinikum Sternberg |
| Basildon University Hospital | Rotkreuzklinikum München |
| St Bartholomew’s Hospital (St Barts) | Stadtspital Zürich Triemli |
| Northwick Park Hospital | Universitätsklinikum Köln |
| Goethe Universität Frankfurt am | |
As the company continues to build out its US commercial team, the launch of NeoNavia in the US remains on schedule and will initially focus on the novel open-tip FlexiPulse needle which has been extensively trialled and used in UK and German hospitals over the past two years.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail anna.eriksrud@neodynamics.com
Aaron Wong, CFO NeoDynamics AB, phone +46735 972 011 or e-mail aaron.wong@neodynamics.com
About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.